This finding is corroborated by recent in vitro data, revealing that α-GPC exerted its beneficial effects through the NGF/TrkA system, knocked down in AD and, consequently, by sustaining the expression level of synaptic vesicle protein synaptophysin (Burgaletto et al., 2021). The gene discussed is NGF; the disease is Alzheimer disease.